SCHEMBL22491533

SCHEMBL22491533

Clc1cccc(Cn2cc(C3CCNCC3)c3ccccc32)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 7/20 0.54
MAOB P27338 2/20 0.54
ALDH1A1 P00352 4/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
HTT P42858 2/20 0.54
KDM4E B2RXH2 1/20 0.54
HSD17B10 Q99714 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
LMNA P02545 4/20 0.51
PARP1 P09874 1/20 0.51
NPSR1 Q6W5P4 2/20 0.47
SMO Q99835 1/20 0.47
HRH2 P25021 1/20 0.46
HTR2A P28223 1/20 0.46
HTR2C P28335 1/20 0.46
HTR2B P41595 1/20 0.46
KLK7 P49862 1/20 0.45
SLC5A1 P13866 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14280694 0.89 SMO (0.55) HTR6ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL4882103 0.86 HTR6 (0.50) HTR6MAOBSMOKLK7HTR1A
SCHEMBL5344809 0.82 SMO (0.49) HTR6ALDH1A1SMN1; SMN2MEN1KMT2A
Hydrochloric Acid SCHEMBL6133473 0.81 HTR6 (0.46) HTR6MEN1KMT2ANPSR1SMO
SCHEMBL14181453 0.80 ALDH1A1 (0.52) HTR6MAOBALDH1A1SMN1; SMN2HTT
SCHEMBL30149780 0.79 KCNH2 (0.47) HTR6MAOBSMOHTR2CHTR2B
SCHEMBL5345509 0.79 CNR1 (0.50) HTR6MEN1KMT2ASMOHTR2C
SCHEMBL5351999 0.79 HTR6 (0.46) HTR6MEN1KMT2ANPSR1SMO
Hydrochloric Acid SCHEMBL6133263 0.78 HTR6 (0.49) HTR6ALDH1A1SMN1; SMN2SMOHTR2C
SCHEMBL5343906 0.78 HTR2A (0.58) HTR6MEN1KMT2ASMOHRH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11420961-B2 Heterocyclic compounds HOFFMANN-LA ROCHE INC. (US) 2022-08-23 US disclosed
EP-3717477-B1 NEW HETEROCYCLIC COMPOUNDS HOFFMANN LA ROCHE (CH) 2022-07-20 EP disclosed
US-20200392125-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2020-12-17 US disclosed
EP-3717477-A1 NEW HETEROCYCLIC COMPOUNDS H. Hoffnabb-La Roche Ag (CH) 2020-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11420961-B2 Heterocyclic compounds LPXN, MLX, CCNY HTR6 3110/4885MAOB 71/4885ALDH1A1 231/4885
US-20200392125-A1 HETEROCYCLIC COMPOUNDS LPXN, MLX, CCNY HTR6 3110/4885MAOB 71/4885ALDH1A1 231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.